M&A Deal Summary

AtriCure Acquires SentreHEART

On August 12, 2019, AtriCure acquired medical products company SentreHEART from Vivo Capital for 300M USD

Acquisition Highlights
  • This is AtriCure’s 3rd transaction in the Medical Products sector.
  • This is AtriCure’s largest (disclosed) transaction.
  • This is AtriCure’s 3rd transaction in the United States.
  • This is AtriCure’s 2nd transaction in California.

M&A Deal Summary
Date 2019-08-12
Target SentreHEART
Sector Medical Products
Buyer(s) AtriCure
Sellers(s) Vivo Capital
Deal Type Add-on Acquisition
Deal Value 300M USD
Advisor(s) Guggenheim Securities (Financial)
Goodwin Procter (Legal)

Target

SentreHEART

Redwood City, California, United States
website
SentreHEART, Inc. is a commercial-stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications. SentreHEART, Inc. was founded in 2005 and is based in Redwood City, California.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AtriCure

Mason, Ohio, United States

website

Category Company
Founded 2000
Sector Medical Products
Employees1,050
Revenue 330M USD (2022)
DESCRIPTION

AtriCure is a medical device company providing atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure was founded in 2000 and is based in Mason, Ohio.

DEAL STATS #
Overall 3 of 3
Sector (Medical Products) 3 of 3
Type (Add-on Acquisition) 3 of 3
State (California) 2 of 2
Country (United States) 3 of 3
Year (2019) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-04 nContact

Morrisville, North Carolina, United States

nContact, Inc. is a privately held developer of innovative cardiac ablation solutions.

Buy $8M

Seller(S) 1

SELLER

Vivo Capital

Investor Investor Investor Investor Investor

website

Category Growth Capital Firm
Founded 1996
PE ASSETS 6.4B USD
Size Mega
Type Sector Focused
DESCRIPTION

Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.

DEAL STATS #
Overall 8 of 12
Sector (Medical Products) 2 of 3
Type (Add-on Acquisition) 1 of 3
State (California) 5 of 6
Country (United States) 7 of 11
Year (2019) 2 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-16 AirXpanders

San Francisco, California, United States

AirXpanders is a medical device company focused on the design, manufacture, sale, and distribution of its AeroForm tissue expander, which is approved for sale in Europe and Australia. AirXpanders is based in San Francisco, California.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-19 Harmony

Plymouth Meeting, Pennsylvania, United States

Harmony is a biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders. Harmony was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Sell -
Mergr

Product

Company

Legal